MedTrace Logo

Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes

NCT00471549 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2007-05-10

No results posted yet for this study

Summary

Diabetes is associated with dyslipidaemia leading to generalized atherosclerosis, cardiovascular disease (CVD) and nephropathy. Osteoprotegerin (OPG), a glycoprotein involved in bone homeostasis, has been implicated in the pathogenesis leading up vessel calcification. Furthermore, CVD in diabetics is associated with increased levels of OPG.

Aim: To investigate whether low dose simvastatin treatment (10-20 mg/day) reduces circulating levels of OPG as well as adhesion molecules (VCAM-1; vascular cell adhesion molecule-1, ICAM; intercellular cell adhesion molecule).

Conditions

Interventions

DRUG

Statin (simvastatin)

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Carl E Mogensen, MD · Aarhus University Hospital, Department M

  • Soren Nielsen, MD, PhD · Aarhus University Hospital, Department M

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-06-30
Completion
1993-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471549 on ClinicalTrials.gov